Finn
ALNY Biotechnology · RNAi · Commercial biotech · Rare disease · Thesis updated November 1, 2026

AMVUTTRA dominates, but Medicare and policy hurdles slow growth

01 Running thesis

A massive launch meets reality

Alnylam has moved from a promising biotech to a real commercial drug company. The key reason is AMVUTTRA. The drug crossed $1 billion in quarterly revenue in mid-2026 and hit $1.15 billion in TTR revenues in the third quarter. The competitive landscape also shifted in Alnylam's favor when rival drug eplontersen failed its Phase 3 study, cementing the company as the leader in ATTR cardiomyopathy.

The bull case is built on this commercial strength. Alnylam leads RNAi, has several approved drugs, and secured a new distribution partnership with BeOne for AMVUTTRA in China and Macau. Its Alnylam 2030 plan targets 25 percent or more total revenue compound annual growth and about a 30 percent non-GAAP operating margin by 2030. Promising Phase 1 data for brezosiran in Huntington's disease adds another potential long-term growth driver.

The bear case centers on the pace of that growth and new policy headwinds. Management expects to land at the low end of its 2026 TTR guidance range. Expanding the sales force has brought in new prescribers, but those doctors are not starting patients on therapy as fast as expected. The initial wave of pent-up demand from second-line patients exhausted faster than anticipated.

The stock also carries regulatory and access questions. A restrictive AMVUTTRA policy implemented by UnitedHealth and a pending CMS 340B rule change both threaten to squeeze volume and price. Heavy Phase 3 research spending and royalty burdens mean profits may not scale as fast as top-line revenue, while FDA scrutiny over marketing adds risk to the story.

Oct 2026▼Q3 2026 earnings noted that prescriber growth is translating to demand slower than expected, shifting 2026 TTR guidance to the low end of its range. New Medicare and UnitedHealth policies also pose headwinds.
Jul 2026→Q2 2026 showed AMVUTTRA crossing $1 billion in quarterly revenue, while a key competitor failed a Phase 3 study. However, management lowered 2026 product revenue guidance as early pent-up demand normalized.
Apr 2026→Q1 2026 confirmed the strength of AMVUTTRA in cardiomyopathy, with $1.036 billion of net product revenue. The update was mixed because management framed 2026 margins near 30 percent and disclosed a new FDA untitled letter risk.
Feb 2026▲Alnylam set initial 2026 net product revenue guidance at $4.9 billion to $5.3 billion. The Alnylam 2030 plan gave investors clearer long-term targets.
Feb 2026▲The 2025 Form 10-K showed Alnylam reached its first full-year GAAP profitability. Product revenue grew to about $3.0 billion, mainly from the TTR franchise.
Oct 2025▼The Q3 2025 filing disclosed a subpoena from the U.S. Attorney's Office related to government price reporting. That added a legal overhang to an otherwise strong AMVUTTRA launch.
02 Business model

Drug sales first, partner checks second

Alnylam makes money in three ways: selling its own drugs, collecting collaboration revenue from partners, and earning royalties on partner-sold drugs. Its four self-marketed products are AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO.

The direct drug business is now much larger than the rest. The TTR franchise is the primary driver, with AMVUTTRA representing a multi-billion dollar annual run rate. This shows how concentrated the business has become around one main therapy.

Partner revenue adds useful funding and geographic reach. Novartis sells Leqvio, Sanofi sells Qfitlia, Roche is partnered on zilebesiran, and BeOne is now the exclusive commercial distributor for AMVUTTRA in Mainland China and Macau. Royalties from Novartis and Sanofi provide high-margin cash flow.

The model breaks if AMVUTTRA loses share or if pricing gets worse. With new access policies from major insurers and proposed Medicare rule changes, the company must prove it can sustainably find and treat new first-line patients while protecting its profit margins.

03 Product portfolio

Approved drugs and big bets

Growth engine

AMVUTTRA

AMVUTTRA treats hATTR amyloidosis with polyneuropathy and ATTR cardiomyopathy. It is the primary growth driver for the entire company.

Steady

ONPATTRO

ONPATTRO treats the polyneuropathy form of hATTR amyloidosis. It is older than AMVUTTRA, and many patients have switched to the newer drug.

Steady

GIVLAARI and OXLUMO

GIVLAARI treats acute hepatic porphyria, and OXLUMO treats primary hyperoxaluria type 1. They give Alnylam rare disease revenue outside TTR.

Cash cow

Leqvio and Qfitlia royalties

Leqvio is sold by Novartis, and Qfitlia is sold by Sanofi. These drugs add high-margin royalty revenue without Alnylam running the sales effort.

Option

Nucresiran

Nucresiran is a next-generation TTR program. A Phase 3 cardiomyopathy study, TRITON-CM, expanded enrollment to 2,250 patients due to lower background event rates.

Option

Zilebesiran

Zilebesiran is an RNAi treatment for hypertension, partnered with Roche. A Phase 3 cardiovascular outcomes trial is expected to start in the second half of 2025.

Option

Brezosiran and obesity program

Brezosiran showed strong reductions in mutant huntingtin in Phase 1, paving the way for Phase 3. Alnylam also has a Phase 1 adipose-targeted obesity program underway.

04 Business segments

Product sales dominate the mix

Net Product Revenues89%growing fast
Net Revenues from Collaborations7%declining
Royalty Revenue4%growing fast

This mix reflects the middle of the 2026 fiscal year, broken into net product revenue, collaboration revenue, and royalty revenue. Product sales dominate entirely.

05 Risk factors

What could break the story

Payer access and 340B cuts

High impact · High odds

A proposed CMS rule change could reduce Medicare reimbursement in the 340B channel, while UnitedHealth implemented a restrictive first-line policy for AMVUTTRA. If these policies stick, they will pressure patient starts and gross-to-net pricing.

We watchQuarterly gross-to-net pricing adjustments, TTR franchise revenue, and hospital ordering behavior.

AMVUTTRA new patient starts stall

High impact · Medium odds

Alnylam expects to land at the low end of its 2026 TTR guidance. Expanding the sales force has brought in new prescribers, but these doctors are struggling with buy-and-bill hurdles and not starting patients as fast as hoped.

We watchU.S. first-line patient starts and comments on new prescriber conversion rates.

FDA promotion scrutiny restricts marketing

Medium impact · Medium odds

In April 2026, the FDA sent Alnylam an untitled letter saying parts of the AMVUTTRA consumer website were false and misleading. That followed a similar September 2025 letter. More action could force changes in marketing and slow patient outreach.

We watchFDA response letters, close-out status for the April 2026 letter, and any visible changes in AMVUTTRA consumer advertising.

Government price reporting investigation

High impact · Low odds

Alnylam received a subpoena from the U.S. Attorney's Office related to government price reporting for its four commercial products. If violations are found, significant financial penalties and management distraction could follow.

We watchNew 10-Q or 10-K disclosures, settlement news, or details on the specific price reporting issues under review.

Pipeline clinical trials fail

Medium impact · Medium odds

Alnylam needs follow-on programs to make the 2030 plan work. TRITON-CM enrollment had to be expanded to offset lower event rates. Failed trials for nucresiran or brezosiran would lower the long-term growth case significantly.

We watchTRITON-CM Phase 3 progress, ALN-6400 updates, and brezosiran Phase 3 initiation timelines.
06 Quick answers

In one breath

What does Alnylam actually do?

Alnylam develops RNAi medicines. RNAi drugs are designed to silence, or turn down, genes that help cause disease.

Why is AMVUTTRA so important to Alnylam?

AMVUTTRA is the main growth engine after its ATTR cardiomyopathy launch. It now generates over a billion dollars in quarterly revenue.

Is Alnylam profitable?

Alnylam reported its first full-year GAAP profitability in 2025. Management targets a 30 percent non-GAAP operating margin by 2030, but royalties and research spending limit how fast profits scale.

What is the biggest risk for ALNY stock?

The biggest risk is that Medicare reimbursement cuts and restrictive insurance policies slow AMVUTTRA growth. Other key risks are FDA scrutiny of promotion and a government price reporting subpoena.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 1, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. Alnylam Q3 2026 earnings call transcript
  2. Alnylam Q2 2026 Form 10-Q
  3. Alnylam Q1 2026 earnings call transcript
  4. Alnylam 2025 Form 10-K
08 Explore the industry

Comparable Biotechnology companies

Companies near Alnylam Pharmaceuticals, Inc. in Finn's Biotechnology industry ranking.

Get started with Finn today